Cite
Han W, Woo JH, Jeon YK, et al. 17p12 deletion in breast cancer predicts resistance to neoadjuvant chemotherapy. Exp Ther Med. 2011;2(5):799-804doi: 10.3892/etm.2011.299.
Han, W., Woo, J. H., Jeon, Y. K., Yang, S. J., Cho, J., Ko, E., Kim, T. Y., Im, S. A., Oh, D. Y., Park, I. A., Hwang, K. T., Moon, H. G., Yang, K. S., & Noh, D. Y. (2011). 17p12 deletion in breast cancer predicts resistance to neoadjuvant chemotherapy. Experimental and therapeutic medicine, 2(5), 799-804. https://doi.org/10.3892/etm.2011.299
Han, Wonshik, et al. "17p12 deletion in breast cancer predicts resistance to neoadjuvant chemotherapy." Experimental and therapeutic medicine vol. 2,5 (2011): 799-804. doi: https://doi.org/10.3892/etm.2011.299
Han W, Woo JH, Jeon YK, Yang SJ, Cho J, Ko E, Kim TY, Im SA, Oh DY, Park IA, Hwang KT, Moon HG, Yang KS, Noh DY. 17p12 deletion in breast cancer predicts resistance to neoadjuvant chemotherapy. Exp Ther Med. 2011 Sep;2(5):799-804. doi: 10.3892/etm.2011.299. Epub 2011 Jun 29. PMID: 22977578; PMCID: PMC3440692.
Copy
Download .nbib